Moleculin Biotech, Inc.
MBRX
$0.77
$0.011.99%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 0.57% | 0.44% | 11.59% | -1.15% | 1.31% |
| Depreciation & Amortization | -72.41% | -74.19% | -70.97% | -32.26% | -9.38% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.19% | 32.49% | 13.40% | -17.22% | -7.53% |
| Operating Income | -32.19% | -32.49% | -13.40% | 17.22% | 7.53% |
| Income Before Tax | 57.13% | -117.56% | 336.21% | -261.60% | -138.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 57.13% | -117.56% | 336.21% | -261.60% | -138.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 57.13% | -117.56% | 336.21% | -261.60% | -138.41% |
| EBIT | -32.19% | -32.49% | -13.40% | 17.22% | 7.53% |
| EBITDA | -32.70% | -33.05% | -13.79% | 17.16% | 7.52% |
| EPS Basic | 95.11% | 77.58% | 121.12% | 64.00% | 60.81% |
| Normalized Basic EPS | 95.31% | 80.28% | 121.27% | 64.00% | 60.81% |
| EPS Diluted | 95.11% | 77.58% | 121.12% | 64.00% | 60.81% |
| Normalized Diluted EPS | 95.31% | 80.28% | 121.27% | 64.00% | 60.81% |
| Average Basic Shares Outstanding | 814.62% | 1,003.40% | 1,010.62% | 904.17% | 508.33% |
| Average Diluted Shares Outstanding | 814.62% | 1,003.40% | 1,010.62% | 904.17% | 508.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |